GW: Pharmaceutical Cannabis To Go Global In 2012
BRITISH GW Pharmaceuticals are set to make their global footprint in 2012 as they move into Australia, Africa, The Middle East, Asia (not China or Japan) while expanding their business in the areas they have already been able to make an impact in – much of Europe and North America.
GW Pharmaceuticals this year are starting three Phase IIa trials on patients with diabetes, metabolic diseases and, in the first quarter of 2012, ulcerative colitis.
This means that they are just working with patients to figure out the prescription dose that they will then proceed to give to all the patients in Phase IIb, where they will then determine if the drug has been as effective at this prescribed dose. Phase III trials for cancer pain are currently being recruited for with use of Sativex also. On GWPharm.com Executive Chairman Geoffry Guy says;
“We have embarked on a substantial Phase III programme for Sativex in cancer pain, a major market opportunity…”
This means a larger scale trial and how the drug compares to the current ‘golden standard’ treatment. When GW scientists proclaim that a drug with no side effects or addiction is rarely seen in pharmaceutical drugs you can imagine that these trials will probably pass with flying colours.
The British Government also agree that there is a major market opportunity for Sativex. This is why they were granted a marketing authorization before The National Institute of Heath and Clinical Excellence (NICE) have even approved it or the Home Office have taken advice from its advisory council, the ACMD, on how to reschedule cannabis. This process is underway, cannabis medicine is being delivered to patients – but at a large financial cost to the NHS and to very few patients that it is intended for and who desperately need it. Reporting on GWPharm.com’s financial section;
GW has delivered another robust set of financial results, with substantially increased revenues yielding a profit for the period and a strong cash position. With Sativex now launched in the UK and Spain, an increasing number of additional European approvals and launches for Sativex now expected and the recent agreement with Novartis to commercialise Sativex across a broad region of the world, Sativex should provide GW with a platform for significant growth in the coming years.
Sativex sales were predominantly lifted by its launch in the UK, Germany, Spain and Denmark during 2011 but it has also been approved in Czech Republic, Italy, with Sweden and Austria expected in the coming months.
A post on Proactiveinvestors.co.uk in November 2011 read:
In the twelve months to end September, GW posted a pre-tax profit of £2.5 million, below last year’s £4.6 million profit, but ahead of expectations for 2011.’
Revenues reached £29.6 million, in line with revenues of £30.7 million in 2010, as Sativex sales jumped 59 percent to £4.4 million, while milestone income amounted to £5.3 million compared to £11.2 million a year earlier. The group’s cash position has increased from £25.2 million at the end of 2010 to £28.3 million.
Other names in the Big Pharma family such as Novartis and Bayer are being contracted for distribution rights over the cannabis product and GW have now admitted beyond all doubt that Sativex is cannabis, delivered in doses similar to a mild smoked joint. [I will be releasing a story chaining the evidence together to hopefully make this an indisputable fact. Black and white. Side by side. Sativex is Cannabis and you can make it yourself.]
A cannabis withdrawal drug is about to be trialled in Australia, shockingly that drug is Sativex, so we have the situation where a pharmaceutical company is ready to supply the Big Pharma companies – with world-wide levels of distribution – with cannabis, to replace cannabis. Their cannabis, not our cannabis… GW are a global organization with a legal profit of over £2million (before tax – boo hoo poor them) for growing 300 metric tonnes of cannabis in wet weight (thats 30 metric tonnes dried/smokable/extractable).
Beyond Europe, we look forward to working with Novartis to commercialise Sativex in a number of key emerging markets.
As for a major market opportunity for Sativex in cancer I wonder how the patient would feel when they had their house raided, were arrested, traumatized, treated like a criminal and potentially a terrorist, detained in poor condition (remember this is a cancer patient), forced to defend themselves in silence in front of a Judge biased with Western Patriarchal and Political prejudices and then faces 14 years in prison. Surely growing 300 metric tonnes of cannabis isn’t cause for a medical defence?
Well it is if you are Geoffry Guy…
Stay tuned and subscribed for more top UK Cannabis News and exposure of the GW Pharm monopoly.